Recurrent Melanoma Completed Phase 1 / 2 Trials for DB00041 (Aldesleukin)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00871481Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic MelanomaTreatment
NCT00553306Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV MelanomaTreatment